NA
SPRO icon

NewEdge Advisors’s Spero Therapeutics SPRO Stock Holding History

NewEdge Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100
Closed -$188 – 4365
2025
Q3 		$188 Hold
100
– – ﹤0.01% 4012
2025
Q2 		$290 Hold
100
– – ﹤0.01% 3853
2025
Q1 		$72 Hold
100
– – ﹤0.01% 3838
2024
Q4 		$103 Hold
100
– – ﹤0.01% 3778
2024
Q3 		$134 Hold
100
– – ﹤0.01% 3706
2024
Q2 		$130 Hold
100
– – ﹤0.01% 3677
2024
Q1 		$172 Hold
100
– – ﹤0.01% 3680
2023
Q4 		$147 Hold
100
– – ﹤0.01% 3620
2023
Q3 		$121 Hold
100
– – ﹤0.01% 3356
2023
Q2 		$145 Hold
100
– – ﹤0.01% 3399
2023
Q1 		$145 Hold
100
– – ﹤0.01% 3325
2022
Q4 		$0 Buy
+100
New +$187 ﹤0.01% 4198

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

NewEdge Advisors's SPRO Position: Q4 2025 in Review

NewEdge Advisors sold out of Spero Therapeutics (SPRO) in Q4 2025, closing a stake of 100 shares — an estimated $188 sold.

NewEdge Advisors first reported a position in SPRO in Q4 2022 and held it in 12 quarters. The position peaked at $290 in Q2 2025. 56 funds tracked by Wall St. Rank hold SPRO as of Q4 2025.

  • NewEdge Advisors reported no remaining Spero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • NewEdge Advisors sold 100 Spero Therapeutics shares in Q4 2025, an estimated $188.
  • NewEdge Advisors first reported a position in Spero Therapeutics in Q4 2022 and held it in 12 quarters.
  • NewEdge Advisors's Spero Therapeutics position peaked at $290 in Q2 2025.
  • 56 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2025.

Based on NewEdge Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.